IP Library Granted Patent US 8,927,533
Granted Patent B2
US 8,927,533 · App. 14/236,359 · Granted Jan 6, 2015

Thio derivatives bearing lactams as potent HDAC inhibitors and their uses as medicaments

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,927,533
App. No.
14/236,359
Granted
Jan 6, 2015
Kind
B2
Abstract

The present invention relates to novel amide compounds of Formula (I), and their use as anti-tumoral and pro-apoptotic agents. The invention includes the use of such compounds in medicine, in relation to cancer disease as well as other diseases where an inhibition of HDAC is responsive, and the pharmaceutical composition containing such compounds.

Claims (73)

1. A compound having the general Formula (I)

wherein,

R 1 is H, (C 1 -C 6 )-alkyl or aryl; or alternatively

R 1 and one R 4 , each being linked to two adjacent carbon atoms, in case n is 2 or 3, are taken together to form a cyclopropane ring;

R 2 is phenyl optionally substituted with halogen, benzyloxy, (C 1 -C 3 )-alkyl or CF 3 ; (C 3 -C 6 )-cycloalkyl; aryl-(C 1 -C 6 )-alkyl wherein the aryl is optionally substituted with benzyloxy, (C 1 -C 3 )-alkyl or CF 3 ;

R 3 is H, PO(OH) 2 , or a group of Formula (II)

—(CO)—R 7   Formula II

R 7 is (C 1 -C 7 )-alkyl, (C 1 -C 6 )-alkoxy or —CH(NH 2 )R 8 ;

R 8 is H, or the side chain of a natural α-amino acid in all possible isomeric forms and selected from the group consisting of glycine, alanine, phenylalanine, valine, leucine, isoleucine, aspartic acid, asparagine, glutamic acid, glutamine, serine, lysine, histidine, methionine, proline, cysteine, threonine, tryptophan, arginine and tyrosine;

R 4 and R 5 are at any occurrence independently H, halogen, (C 1 -C 6 )-alkyl, or alternatively, when n is 2 or 3, one R 4 and one R 5 , each being linked to two adjacent carbon atoms, are taken together to form a cyclopropane ring;

R 6 is H or alternatively,

R 2 and R 6 are taken together to form a five- to six-membered heterocycle which can be optionally fused with an aryl moiety;

-A-E- is —(CO)—(NR 9 )— or —(NR 9 )—(CO)—;

R 9 is H or (C 1 -C 3 )-alkyl;

m is an integer comprised between 0 to 3;

n is an integer comprised between 0 to 3 with the proviso that when is 2 or 3, each of R 4 and R 5 can adopt different meaning at each occurrence;

the symbol means that the carbon atom bearing said symbol can adopt a R or S configuration;

the symbol ◯ can be absent, but if present it means that the cycle can be partially unsaturated with the proviso that when the carbon atom bearing R 4 is involved in a double bond, R 5 is absent;

their tautomers, their geometrical isomers, their optically active forms and their racemate forms, as well as their pharmaceutically acceptable salts thereof.

2. A compound according to claim 1 , wherein n is 1 or 2.

3. A compound according to claim 1 , wherein m is 1 or 2.

4. A compound according to claim 1 , wherein said optically active forms are enantiomers and diastereomers.

5. A pharmaceutical composition containing a compound according to claim 1 as the active ingredient in mixtures with a pharmaceutically acceptable vehicle and/or excipient.

6. A method for the treatment of a pathological state selected from the group consisting of cancer disease consisting of ovarian, breast, colon, head and neck, acute monocytic leukemia, T-Lymphoma, chronic myeloid leukemia and non-small cell lung cancer, comprising administering an effective amount of a compound of claim 1 to a patient in need thereof.

7. Method according to claim 6 where the cancer is a metastatic form of cancer.

8. The method of claim 6 , wherein the effective amount is from 0.01 mg/kg to 100 mg/kg.

9. The method of claim 8 , wherein the effective amount is from 0.05 mg/kg to 50 mg/kg.

10. Process for synthesizing compounds of claim 1 , by reacting compounds of Formula (III)

wherein R 2 , R 3 and R 6 and m are as described in claim 1 , with compounds of Formula (IV) salified or not

wherein R 1 , R 4 and R 5 and n are as described in claim 1 , in a polar aprotic solvent in the presence of a coupling agent.

11. A compound according to claim 1 selected from the group consisting of:

thioacetic acid S—{(S)-6-[((S)-4-oxo-azetidine-2-carbonyl)-amino]-6-phenylcarbamoyl-hexyl}ester,

thioacetic acid S—[(S)-6-[((S)-6-oxo-piperidine-2-carbonyl)-amino]-6-(4-trifluoromethyl-benzylcarbamoyl)-hexyl]ester,

thioacetic acid S—{(S)-6-(3-benzyloxy-benzylcarbamoyl)-6-[((S)-6-oxo-piperidine-2-carbonyl)-amino]-hexyl}ester,

thioacetic acid S—{(S)-7-(3,4-dihydro-1H-isoquinolin-2-yl)-7-oxo-6-[((S)-6-oxo-piperidine-2-carbonyl)-amino]-heptyl}ester,

thioacetic acid S—[(S)-6-[((S)-6-oxo-piperidine-2-carbonyl)-amino]-6-(2-m-tolyl-ethylcarbamoyl)-hexyl]ester,

thioacetic acid S—{(S)-6-[((R)-6-oxo-piperidine-2-carbonyl)-amino]-6-phenylcarbamoyl-hexyl}ester, thioacetic acid S—{(S)-6-[((S)-6-oxo-piperidine-2-carbonyl)-amino]-6-phenylcarbamoyl-hexyl}ester,

thioacetic acid S—{(S)-6-[((S)-6-oxo-piperidine-2-carbonyl)-amino]-6-p-tolylcarbamoyl-hexyl}ester,

thioacetic acid S—{(S)-6-[((S)-6-oxo-piperidine-2-carbonyl)-amino]-6-m-tolylcarbamoyl-hexyl}ester,

thioacetic acid S—{(S)-6-[((S)-6-oxo-piperidine-2-carbonyl)-amino]-6-cyclopentylcarbamoyl-hexyl}ester,

thioacetic acid S—{(S)-6-[((3R*,4S*)-2-oxo-4-phenyl-pyrrolidine-3-carbonyl)-amino]-6-phenylcarbamoyl-hexyl}ester,

thioacetic acid S—{(S)-6-[((3R*,4R*)-2-oxo-4-phenyl-pyrrolidine-3-carbonyl)-amino]-6-phenylcarbamoyl-hexyl}ester,

thioacetic acid S—{(S)-6-[((R)-5-oxo-pyrrolidine-2-carbonyl)-amino]-6-phenylcarbamoyl-hexyl}ester,

thioacetic acid S—{(S)-6-[(R*)-(2-oxo-piperidine-3-carbonyl)-amino]-6-phenyl carbamoyl-hexyl}ester,

(S)-6-oxo-piperidine-2-carboxylic acid ((S)-6-mercapto-1-phenylcarbamoyl-hexyl)-amide,

(S)-6-oxo-piperidine-2-carboxylic acid ((S)-1-cyclopentylcarbamoyl-6-mercapto-hexyl)-amide,

(S)-6-oxo-piperidine-2-carboxylic acid [(S)-1-(3-benzyloxy-benzylcarbamoyl)-6-mercapto-hexyl]-amide,

(S)-6-oxo-piperidine-2-carboxylic acid [(S)-6-mercapto-1-(4-trifluoromethyl-benzylcarbamoyl)-hexyl]-amide,

(S)-4-oxo-azetidine-2-carboxylic acid ((S)-6-mercapto-1-phenylcarbamoyl-hexyl)-amide,

(3S,4S)-2-oxo-4-phenyl-pyrrolidine-3-carboxylic acid ((S)-6-mercapto-1-phenylcarbamoyl-hexyl)-amide,

(3R,4R)-2-oxo-4-phenyl-pyrrolidine-3-carboxylic acid ((S)-6-mercapto-1-phenylcarbamoyl-hexyl)-amide,

(3R,4S)-2-oxo-4-phenyl-pyrrolidine-3-carboxylic acid ((S)-6-mercapto-1-phenylcarbamoyl-hexyl)-amide,

(3S,4R)-2-oxo-4-phenyl-pyrrolidine-3-carboxylic acid ((S)-6-mercapto-1-phenylcarbamoyl-hexyl)-amide,

(S)-6-oxo-piperidine-2-carboxylic acid [(S)-1-(3,4-dihydro-1H-isoquinoline-2-carbonyl)-6-mercapto-hexyl]-amide,

(R)-5-oxo-pyrrolidine-2-carboxylic acid ((S)-6-mercapto-1-phenylcarbamoyl-hexyl)-amide,

(S)-6-oxo-piperidine-2-carboxylic acid [(S)-6-mercapto-1-(2-m-tolyl-ethylcarbamoyl)-hexyl]-amide,

(R)-2-oxo-piperidine-3-carboxylic acid ((S)-6-mercapto-1-phenylcarbamoyl-hexyl)-amide,

(S)-2-oxo-piperidine-3-carboxylic acid ((S)-6-mercapto-1-phenylcarbamoyl-hexyl)-amide,

(R)-6-oxo-piperidine-2-carboxylic acid ((S)-6-mercapto-1-phenylcarbamoyl-hexyl)-amide,

thiocarbonic acid ethyl ester {(S)-6-[((S)-6-oxo-piperidine-2-carbonyl)-amino]-6-phenylcarbamoyl-hexyl}ester,

thioisobutyric acid S—{(S)-6-[((S)-6-oxo-piperidine-2-carbonyl)-amino]-6-phenylcarbamoyl-hexyl}ester,

thioacetic acid S—{(S)-6-[((S)-5-oxo-pyrrolidine-2-carbonyl)-amino]-6-phenylcarbamoyl-hexyl}ester,

thioacetic acid S—{(S)-6-[((S)-5-oxo-pyrrolidine-2-carbonyl)-amino]-6-m-tolylcarbamoyl-hexyl}ester,

thioacetic acid S—{(S)-6-[((R)-1-methyl-5-oxo-pyrrolidine-2-carbonyl)-amino]-6-phenylcarbamoyl-hexyl}ester,

thiocarbonic acid ethyl ester {(S)-6-[((R)-5-oxo-pyrrolidine-2-carbonyl)-amino]-6-phenylcarbamoyl-hexyl}ester,

thioacetic acid S—{(S)-6-[((R)-5-oxo-pyrrolidine-2-carbonyl)-amino]-6-m-tolylcarbamoyl-hexyl}ester,

thioacetic acid S—{(S)-6-[((R)-1-methyl-5-oxo-pyrrolidine-2-carbonyl)-amino]-6-m-tolylcarbamoyl-hexyl}ester,

thioacetic acid S—[(S)-6-[((R)-5-oxo-pyrrolidine-2-carbonyl)-amino]-6-(3-trifluoromethyl-phenylcarbamoyl)-hexyl]ester,

thioacetic acid S—{(S)-6-[((S)-1-methyl-6-oxo-piperidine-2-carbonyl)-amino]-6-phenylcarbamoyl-hexyl}ester,

(S)-1-methyl-6-oxo-piperidine-2-carboxylic acid ((S)-6-mercapto-1-phenylcarbamoyl-hexyl)-amide,

(S)-6-oxo-piperidine-2-carboxylic acid ((S)-6-mercapto-1-m-tolylcarbamoyl-hexyl)-amide,

(S)-6-oxo-piperidine-2-carboxylic acid ((S)-6-mercapto-1-p-tolylcarbamoyl-hexyl)-amide, and

thioacetic acid S—{(S)-6-[((S)-6-oxo-1,2,3,6-tetrahydro-pyridine-2-carbonyl)-amino]-6-phenylcarbamoyl-hexyl}ester.

Assignments (3)
CHANGE OF ADDRESS Recorded Oct 15, 2019
From: ALFASIGMA S.P.A.
To: ALFASIGMA S.P.A.
Reel/Frame 050727/0652 →
MERGER Recorded Nov 14, 2017
From: SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A.
To: ALFASIGMA S.P.A.
Reel/Frame 044760/0906 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 7, 2014
From: GIANNINI, GIUSEPPE; CABRI, WALTER; BATTISTUZZI, GIANFRANCO; VIGNOLA, DAVIDE; FANTO', NICOLA; PISANO, CLAUDIO; VESCI, LOREDANA
To: SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A.
Reel/Frame 032614/0004 →